| International Session（Symposium）4(JSGE・JGES) |
| Fri. November 22nd 9:30 - 12:00 Room 11: Portopia Hotel South Wing Topaz |
| Functional Dyspepsia and Visceral Obesity | |||
| Mamoru Ito1, Jiro Miyaike3, Shigeru Harasawa2 | |||
| 1Internal Medicine, Okayama Saiseikai General Hospital, 2Saiseikai Kawaguchi General Hospital, 3Saiseikai Imabari Hospital | |||
|
|||
|
|||
| [Purpose] A prospective multicenter collaborative study (DMETS study, UMIN000001974) is currently underway (scheduled to end in March, 2019) to examine the difference in the treatment effect of PPI in the presence of metabolic syndrome. Herein, we examined the visceral obesity and the PPI treatment effect of the 68 patients who initially participated in the DMETS study from 2009 to 2012. [Methods] Subjects were aged 20 years or older diagnosed FD with ROME III. EGD and CT scan were performed. The visceral fat was measured from the CT value. Patients were treated with PPI for 4 weeks, and QOL were investigated using GSRS and SF-36. [Results] Among 68 patients, 8cases were excluded because of the exclusion criteria, withdrawal of consent, and lack of follow up visit. 60cases, 24males, 36females, age23-75(Ave51.7) were analyzed. Based on visceral fat, they were divided into two groups, 10cases of Visceral Obesity(VO) group with visceral fat of 100cm2 or more, and 50cases of Non-Obesity(NO) group with less than 100cm2. With PPI administration, improvement of overall FD symptom was 69.0%. There was a somewhat correlation between the change in GSRS reflux symptom score and visceral fat (correlation coefficient -0.2457,p=0.0584) but no statistical difference. [Conclusion] The association between obesity and the PPI treatment effect was not significant. The limitations of this study includes small sample size, hence it needs to be concluded with further research. |
|||
|
Index Term 1: Functional Dyspepsia Index Term 2: Visceral Obesity |
|||
| Page Top | |||